Literature DB >> 3920112

Non-A, non-B posttransfusion hepatitis--a decade later.

R L Koretz, O Stone, M Mousa, G L Gitnick.   

Abstract

We have followed up 69 patients who developed non-A, non-B posttransfusion hepatitis in 1972-1978. Chronic hepatitis, defined by biochemical criteria, was observed in 46 patients (67%), the majority of whom subsequently failed to resolve the abnormalities. Chronic hepatitis was a sequela of non-A, non-B posttransfusion hepatitis less often after the blood bank changed to a policy of all volunteer donors. (However, this association may be explained by other coexistent factors.) The alanine aminotransferase level was more likely to be abnormal than the aspartate aminotransferase level during the chronic phase of non-A, non-B posttransfusion hepatitis. By actuarial means it was calculated that the probability of developing normal enzymes after 6-10 yr was 0.47. However, in spite of this high incidence of biochemical disease, virtually all of the patients have remained asymptomatic. Histologic evidence of cirrhosis has been obtained in 4 of these patients, but in only 2 patients at most has clinical evidence of hepatic failure supervened.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3920112     DOI: 10.1016/s0016-5085(85)80087-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

Review 1.  Non-A, non-B hepatitis.

Authors:  T N Dewar
Journal:  West J Med       Date:  1990-08

2.  The prevalence of hepatitis C virus infection in Texas: implications for future health care.

Authors:  Kanthi Yalamanchili; Sherif Saadeh; Rita Lepe; Gary L Davis
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-01

Review 3.  Hepatitis C virus and transfusion transmitted liver disease: review.

Authors:  J C Underwood
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

4.  Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.

Authors:  D D Douglas; J Rakela; H J Lin; F B Hollinger; H F Taswell; A J Czaja; J B Gross; M L Anderson; K Parent; C R Fleming
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

5.  Effects of interferon-alpha on serum hepatitis C virus in patients with chronic hepatitis C.

Authors:  M Shibata; T Kumada; M Yamada; S Nakano; T Kudo; T Morishima
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

6.  Detection of 2',5' oligoadenylate synthetase activity in acute viral hepatitis with special reference to histologic features in the acute stage.

Authors:  T Okuno; M Shindo; K Arai; M Matsumoto; M Takeda; K Kashima; Y Sokawa
Journal:  Gastroenterol Jpn       Date:  1991-04

Review 7.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

8.  2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.

Authors:  T Okuno; M Shindo; K Arai; M Matsumoto; M Takeda; K Kashima; Y Sokawa
Journal:  Gastroenterol Jpn       Date:  1991-10

9.  Open heart surgery in children of Jehovah's Witnesses: extreme hemodilution on cardiopulmonary bypass.

Authors:  J I Stein; H Gombotz; B Rigler; H Metzler; C Suppan; A Beitzke
Journal:  Pediatr Cardiol       Date:  1991-07       Impact factor: 1.655

10.  Prevalence of hepatitis C virus antibody in a liver transplantation population.

Authors:  L el-Ashmawy; T Hassanein; J S Gavaler; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1992-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.